Novocure LTD Form 4 insider transactions

NovoCure's Chief Operating Officer, Mukund Paravasthu, disposed of shares to cover tax withholding obligations related to Restricted Stock Unit vesting.

NovoCure's EVP and President of Oncology, Frank X. Leonard, disposed of 966 ordinary shares to cover tax obligations related to Restricted Stock Unit vesting.

NovoCure's Chief Human Resources Officer, Michal Nath Puri, reported the disposition of 752 ordinary shares to cover tax obligations related to Restricted Stock Unit vesting.

NovoCure Ltd's CEO, Ashley Cordova, has established a 10b5-1 plan to acquire 81,550 ordinary shares on September 5, 2025.

NovoCure's Chief Financial Officer, Christoph Brackmann, acquired 20,000 ordinary shares for approximately $231,800 through multiple open market purchases.

NovoCure Ltd.'s Chief Human Resources Officer, Michal Nath Puri, acquired 833 ordinary shares at $15.13 per share through the company's Employee Share Purchase Plan.

NovoCure's EVP and President of Oncology, Frank X. Leonard, acquired 833 ordinary shares through the company's Employee Share Purchase Plan at a discounted price.

NovoCure Ltd. Director Asaf Danziger acquired 833 ordinary shares at $15.13 per share through the company's 2025 Employee Share Purchase Plan.

NovoCure Ltd's Chief Executive Officer, Ashley Cordova, acquired 833 ordinary shares at a price of $15.13 per share through the company's Employee Share Purchase Plan.

NovoCure Ltd.'s General Counsel, Ben Arye Barak, reported a pre-planned acquisition of 769 ordinary shares at $15.13 per share, scheduled for June 30, 2025, via the company's Employee Share Purchase Plan.

NovoCure Ltd. Director Gabriel Leung has been granted 11,215 restricted stock units and options to purchase 16,697 ordinary shares, aligning his interests with shareholders.

NovoCure Ltd. Director Kristin Stafford has reported the acquisition of 11,215 restricted stock units and 16,697 stock options as part of her compensation, according to a recent SEC Form 4 filing.

NovoCure Ltd. Director Martin J. Madden has been granted 33,393 stock options with an exercise price of $16.72 per share, as disclosed in a recent SEC Form 4 filing.

NovoCure Ltd. Director Jeryl L. Hilleman was granted 11,215 restricted stock units and options to purchase 16,697 ordinary shares, effective June 4, 2025, as part of her compensation.

NovoCure Ltd. Director Allyson J. Ocean was granted 11,215 restricted stock units and options to purchase 16,697 ordinary shares as part of her compensation, aligning her interests with shareholders.

NovoCure Ltd. Director Timothy J. Scannell was granted 11,215 restricted stock units and 16,697 stock options as part of his compensation, aligning his interests with shareholders.

NovoCure Ltd. Director David Hung was granted 11,215 restricted stock units and options to purchase 16,697 ordinary shares, effective June 4, 2025, as part of his compensation.

NovoCure Ltd. Director W. Anthony Vernon was granted 11,215 restricted stock units and 16,697 stock options as part of his compensation, aligning his interests with shareholders.

NovoCure Ltd's EVP and President of Oncology, Frank X. Leonard, was granted 179,426 restricted share units, aligning his interests with long-term company performance.

NovoCure Ltd. Director Kristin Stafford sold 999 ordinary shares on June 3, 2025, at a weighted average price of $17.2762 per share, solely to satisfy tax withholding obligations related to vested Restricted Stock Units.

NovoCure Ltd. Director Gabriel Leung reported the sale of 999 ordinary shares valued at a weighted average price of $17.3146 per share, a transaction explicitly stated as non-discretionary and solely for tax withholding purposes related to Restricted Stock Unit vesting.

NovoCure Ltd. Director Martin J. Madden sold 999 ordinary shares at a weighted average price of $17.1928 to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

NovoCure Ltd. Director Timothy J. Scannell sold 999 ordinary shares at a weighted average price of $17.3165 to satisfy tax withholding obligations related to vested Restricted Stock Units.

NovoCure Ltd. Director Jeryl L. Hilleman sold 999 ordinary shares on June 3, 2025, at a weighted average price of $17.2638 per share, solely to satisfy tax withholding obligations related to vested Restricted Stock Units.

NovoCure Ltd. Director Allyson J. Ocean sold 999 ordinary shares at a weighted average price of $17.2863 to satisfy tax withholding obligations related to vested Restricted Stock Units.

NovoCure Ltd. Director W. Anthony Vernon sold 999 ordinary shares on June 3, 2025, at a weighted average price of $17.3466, solely to satisfy tax withholding obligations from Restricted Stock Unit (RSU) vesting.

NovoCure Ltd. Director David Hung sold 999 ordinary shares at a weighted average price of $17.2968 to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Frank X. Leonard, EVP and President of NovoCure Oncology, has sold 30,196 ordinary shares of NovoCure Ltd. through a pre-arranged Rule 10b5-1 trading plan.

Mukund Paravasthu, Chief Operating Officer of NovoCure Ltd, sold 592 ordinary shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Chief Medical Officer of NovoCure, Nicolas Leupin, reports acquiring shares and stock options in the company.